 Your new post is loading...
|
Scooped by
HAS-veille
May 21, 2023 7:43 AM
|
Abstract Background In the United States, more than 30,000 cases of mpox (formerly known as monkeypox) had occurred as of March 1, 2023, in an outbreak disproportionately affecting transgende
|
|
Scooped by
HAS-veille
May 2, 2023 7:09 AM
|
The widespread outbreak of the monkeypox virus (MPXV) recognized in 2022 poses new challenges for public healthcare systems worldwide. With more than …
|
|
Scooped by
HAS-veille
March 29, 2023 9:17 AM
|
The relative contribution of the respiratory route to transmission of mpox (formerly
known as monkeypox) is unclear. We review the evidence for respiratory transmission
of monkeypox virus (MPXV), examining key works from animal models, human outbreaks
and case reports, and environmental studies. Laboratory experiments have initiated
MPXV infection in animals via respiratory routes. Some animal-to-animal respiratory
transmission has been shown in controlled studies, and environmental sampling studies
have detected airborne MPXV.
|
|
Scooped by
HAS-veille
March 15, 2023 4:23 AM
|
The UK experienced a national outbreak of mpox (formerly known as monkeypox) disease that started in May, 2022, as did many other countries worldwide,…
|
|
Scooped by
HAS-veille
March 6, 2023 1:09 AM
|
The early epidemiology of the 2022 monkeypox epidemic in non-endemic countries differs substantially from the epidemiology previously reported from en…
|
|
Scooped by
HAS-veille
March 3, 2023 12:01 AM
|
This report describes interim clinical treatments for severe mpox developed following the evaluation of treatment data, cases, input from clinicians, and more.
|
|
Scooped by
HAS-veille
February 6, 2023 6:25 AM
|
|
|
Scooped by
HAS-veille
February 6, 2023 1:13 AM
|
Mpox mainly causes skin injuries, but severe complications and even death can occur in vulnerable individuals. This systematic review and meta-analysis revealed
|
|
Scooped by
HAS-veille
January 25, 2023 2:59 AM
|
WHO has declared human mpox (formerly known as monkeypox) a global public health emergency since July, 2022. When case numbers were increasing, so did…
|
|
Scooped by
HAS-veille
January 19, 2023 3:35 AM
|
Mpox Surveillance in Wastewater In this report, the use of wastewater to conduct surveillance for the presence and spread of mpox in California is described.
|
|
Scooped by
HAS-veille
January 18, 2023 3:17 AM
|
In a Policy Forum piece, Dr. Nicola Low and colleagues define the research agenda for Mpox virus and transmission through sexual contact.
|
|
Scooped by
HAS-veille
January 12, 2023 6:58 AM
|
Dwindling case counts obscure an important reality: The global footprint of mpox, which until a few years ago could only be contracted in parts of Africa, has expanded substantially.
|
|
Scooped by
HAS-veille
January 3, 2023 1:58 AM
|
A multicountry outbreak of monkeypox has gained global attention. Basic research including structural and immunological investigation on monkeypox vir…
|
|
|
Scooped by
HAS-veille
May 12, 2023 2:33 AM
|
The WHO ended the global health emergency for mpox on Thursday, saying that while the virus continues to spread internationally, steady progress has been made in controlling the outbreak.
|
|
Scooped by
HAS-veille
April 14, 2023 3:41 AM
|
Since 16 May 2022, and as of 4 April 2023, 21 170 cases of mpox (formerly known as monkeypox) have been reported by countries within the European Union/European Economic Area (EU/EEA).
|
|
Scooped by
HAS-veille
March 16, 2023 6:52 AM
|
An abstract is unavailable.
|
|
Scooped by
HAS-veille
March 14, 2023 10:53 AM
|
|
|
Scooped by
HAS-veille
March 3, 2023 12:15 AM
|
Undetected infection and delayed isolation of infected individuals are key factors driving the monkeypox virus (now termed mpox virus or MPXV) outbreak. To enable earlier detection of MPXV infection, we developed an image-based deep convolutional neural network (named MPXV-CNN) for the identification of the characteristic skin lesions caused by MPXV. We assembled a dataset of 139,198 skin lesion images, split into training/validation and testing cohorts, comprising non-MPXV images (n = 138,522) from eight dermatological repositories and MPXV images (n = 676) from the scientific literature, news articles, social media and a prospective cohort of the Stanford University Medical Center (n = 63 images from 12 patients, all male). In the validation and testing cohorts, the sensitivity of the MPXV-CNN was 0.83 and 0.91, the specificity was 0.965 and 0.898 and the area under the curve was 0.967 and 0.966, respectively. In the prospective cohort, the sensitivity was 0.89. The classification performance of the MPXV-CNN was robust across various skin tones and body regions. To facilitate the usage of the algorithm, we developed a web-based app by which the MPXV-CNN can be accessed for patient guidance. The capability of the MPXV-CNN for identifying MPXV lesions has the potential to aid in MPXV outbreak mitigation. A deep-learning algorithm was developed to identify skin lesions caused by the mpox virus and was then implemented in a web-based app designed for patient use.
|
|
Scooped by
HAS-veille
February 7, 2023 4:17 AM
|
|
|
Scooped by
HAS-veille
February 6, 2023 1:14 AM
|
|
|
Scooped by
HAS-veille
February 1, 2023 2:12 AM
|
The recent global outbreak of the monkeypox (mpox) virus in humans was declared a public health emergency by the World Health Organization in July 2022. The smallpox and mpox vaccine (JYNNEOS; Modified Vaccinia Ankara-Bavarian Nordic; MVA-BN), provided as a two-dose regimen, is currently the primary vaccine utilized against mpox. However, the efficacy of MVA-BN against mpox has never been demonstrated in clinical trials to date. Due to the limited supply of vaccines, the World Health Organization has recommended prioritizing the vaccination of high-risk groups. We evaluated the real-world effectiveness of a single, subcutaneous dose of MVA-BN in this observational, retrospective cohort study, which included the analysis of electronic health records of all members of Clalit Health Services eligible for the vaccine on 31 July 2022. We used a Cox proportional hazards regression model with time-dependent covariates to estimate the association between vaccination and mpox while adjusting for sociodemographic and clinical risk factors. In an analysis of 2,054 male individuals who met vaccine eligibility criteria, 1,037 (50%) were vaccinated during the study recruitment period and completed at least 90 d of follow-up. During the study period, 5 and 16 infections were confirmed in vaccinated and unvaccinated individuals, respectively. The adjusted vaccine effectiveness was estimated at 86% (95% confidence interval, 59–95%). Our results suggest that a single dose of subcutaneous MVA-BN in this high-risk cohort is associated with a significantly lower risk of MPXV infection. Effectiveness of one subcutaneous dose of MVA-BN, the smallpox and mpox vaccine, was estimated to be 86% in a cohort of vaccine-eligible males in Israel, supporting its use to curtail the outbreak of mpox virus.
|
|
Scooped by
HAS-veille
January 19, 2023 11:54 PM
|
This report describes epidemiology of mpox cases in six African counties and additional cases associated with travel that followed during 2018–2021.
|
|
Scooped by
HAS-veille
January 18, 2023 7:14 AM
|
|
|
Scooped by
HAS-veille
January 16, 2023 12:34 AM
|
This decision analytic model estimates the levels of community testing, contract tracing, and vaccination required to reduce the effective reproduction number of the mpox virus among the high-risk group of men who have sex with men.
|
|
Scooped by
HAS-veille
January 3, 2023 4:03 AM
|
Drug Sensitivity of Mpox Isolates from 12 patients with mpox virus infection showed in vitro sensitivity at clinically achievable levels to the antiviral agents tecovirimat, cidofovir, an
|
Scoop.it!
